trending Market Intelligence /marketintelligence/en/news-insights/trending/xtnjheug3i-ktderrpqrfw2 content esgSubNav
In This List

WuXi Biologics to build manufacturing facility in northern China

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


WuXi Biologics to build manufacturing facility in northern China

WuXi Biologics (Cayman) Inc. said it will build an integrated biologics facility in Shijiazhuang, the capital of China's Hebei province.

Biologics centers develop and manufacture biologic medical products using living microorganisms, plants or animal cells.

WuXi Biologics said the initial phase of the center is expected to be operational in 2020.

China-based WuXi Biologics is a provider of discovery, research, development and manufacturing of biologics services.